Compound_Name,CAS_Number,SMILES,Molecular_Formula,Molecular_Weight,LogP,Rotatable_Bonds,Primary_Target,Target_Gene,K_i_nM,K_i_Source_PMID,K_d_nM,k_off_per_min,tau_residence_min,tau_method,t_onset_min,t_onset_method,EC50_nM,EC50_Assay,t_half_plasma_h,Cmax_ng_mL,AUC_ng_h_mL,Vd_L_kg,Clearance_L_h_kg,Protein_Binding_percent,API_absolute,API_relative,API_CI_lower,API_CI_upper,AKR,EMC,NCR_percent,PARI,Arrest_Level,Confidence_Grade,Clinical_Status
Nalfurafine,152658-17-8,C[C@@H]1[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC=C(C)C)Cc1ccccc1-4,C28H32N2O3,445.56,3.8,2,Kappa-opioid receptor,OPRK1,0.075,15707643,0.075,EST,EST,Estimated from clinical duration,20,Clinical antipruritic onset,0.025,GTPÎ³S binding KOR,4.5,NR,NR,NR,NR,NR,EST,EST,EST,EST,EST,-0.35,45,0.4,Level 2-3,MODERATE,FDA approved Japan
Everolimus,159351-69-6,COC1CC(CC(C)C2CC(=O)C(C)C(O)C(OC)C(=O)C(C)CC(C)C(=O)C(C(C)CC(CC=CC=CC=C(C)C(CC(C)C(=O)O2)OC)C)OC)OC1,C53H83NO14,958.22,5.1,7,mTOR Complex 1,MTOR,0.6,NR,0.6,0.0069,145,Estimated from rapamycin SAR,2880,Autophagy onset slower than rapamycin,1.8,Cell proliferation inhibition,30,14.4,634,4.3,0.35,74,EST,EST,EST,EST,0.55,-0.38,NA,0.42,Level 3,MODERATE-HIGH,FDA approved
Temsirolimus,162635-04-3,C2H5OC(=O)CCC(=O)O[C@H]1C[C@@H](C)C[C@H]2OC(=O)[C@H](C)C(C)=CC=C[C@@H](C)[C@@H](O[C@H]3O[C@H](C)[C@@H](O)[C@H](OC)[C@H]3O)C(C)=CC(C)C(=O)[C@]2(O)C[C@@H]1OC,C56H87NO16,1030.29,5.3,11,mTOR Complex 1,MTOR,0.8,NR,0.8,0.0058,172,Estimated from class,3600,Very slow functional onset,2.5,mTOR signaling inhibition,17.3,295,2212,172,10.6,87,EST,EST,EST,EST,0.48,-0.37,NA,0.45,Level 3,MODERATE,FDA approved
Muscimol,2763-96-4,C1=CN=C(O1)C(=O)N,C4H6N2O2,114.1,-1.1,0,GABA-A receptor,GABRA1,0.3,6144558,0.3,0.5,2,Very rapid dissociation,2,Immediate CNS depression,0.5,GABA-A chloride flux,0.5,NR,NR,0.6,NR,<10,EST,EST,EST,EST,0.04,-0.65,60,0.1,Level 2-3,MODERATE,Research only toxin
Diazepam,439-14-5,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C16H13ClN2O,284.74,2.8,1,GABA-A receptor,GABRA1,18,6253801,18,0.033,30,Estimated from clinical duration,30,Clinical anxiolytic onset,18,GABA-A positive modulation,43,390,15600,1.1,0.027,98,EST,EST,EST,EST,1.0,-0.3,35,0.25,Level 2,HIGH,FDA approved
Propofol,2078-54-8,CC(C)C1=CC(=C(C(=C1)C(C)C)O)C(C)C,C12H18O,178.27,3.8,0,GABA-A receptor,GABRA1,4.5,8502498,4.5,0.2,5,Very rapid offset for anesthetic,0.5,Immediate consciousness loss,4.5,GABA-A chloride current,2,1850,6200,3.5,27.8,98,EST,EST,EST,EST,0.02,-0.75,75,0.6,Level 3,MODERATE-HIGH,FDA approved anesthetic
Adenosine,58-61-7,NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O,C10H13N5O4,267.24,-1.1,2,Adenosine A1 receptor,ADORA1,70,8987793,70,0.4,2.5,Literature A1 receptor,5,Sleep pressure onset,73,A1 receptor cAMP inhibition,0.003,NR,NR,0.6,NR,<5,EST,EST,EST,EST,0.5,-0.25,NA,0.15,Level 1-2,MODERATE,Endogenous FDA approved IV
Curcumin,458-37-7,COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O,C21H20O6,368.38,3.2,8,Multiple,MULTIPLE,50000,14570043,50000,5,0.2,Very rapid dissociation multi-target,1440,Very slow if any,50000,Various weak effects,6.8,1840,12950,1.5,1.2,90,EST,EST,EST,EST,0.00014,-0.05,NA,0.02,Level 0-1,LOW,Supplement
Quercetin,117-39-5,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,C15H10O7,302.24,1.5,1,SIRT1 Multiple,SIRT1,80000,24931768,80000,8,0.125,Very rapid dissociation,1440,Very slow if any,80000,Weak SIRT1 activation,1.8,492,2460,2.4,0.28,>99,EST,EST,EST,EST,0.00001,-0.03,NA,0.01,Level 0-1,LOW,Supplement
